Trial observers say ‘game over’ for XBiotech's failed PhIII cancer study, the latest in a long line of setbacks
There’s more bad news to report for XBiotech $XBIT.
A few weeks after European regulators snubbed the company’s application to start marketing its dubious …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
